Tirzepatide for Psoriatic Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.The study will last up to 12 months.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must have been on ixekizumab for about 3 months before starting tirzepatide, and you cannot have used tirzepatide or similar medications before.
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for people with active Psoriatic Arthritis (PsA) who are also overweight or obese and have at least one weight-related health issue. Participants should already be receiving ixekizumab therapy as part of their standard care.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants continue on ixekizumab and take tirzepatide administered subcutaneously as per label
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tirzepatide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University